Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Alexander Dettmer as Chief Financial Officer, effective July 1, 2020.
Laupheim, Germany and Milford, MA, USA, June 17, 2020 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Alexander Dettmer (41) as Chief Financial Officer (CFO), effective July 1, 2020. Mr. Dettmer brings 15 years of financial, business development and leadership experience with a focus on driving operational excellence in the healthcare and life sciences sectors. At Rentschler Biopharma, he will be heading the finance, supply chain management, information technology and legal functions. Mr. Dettmer succeeds Stefan Rampf, who will be leaving the company, effective June 30, 2020 to pursue a new opportunity.
Prof. Dr. Nikolaus F. Rentschler, Chairman of the Board of Rentschler Biopharma, said: “It is my great pleasure to announce the appointment of Alexander Dettmer as our new CFO. He is a highly respected professional with a demonstrated record of success, deeply rooted in his commitment to sustainable value creation. I am therefore convinced, that he is an ideal match for our management team at Rentschler Biopharma. I would also like to take the opportunity to thank Stefan Rampf for his exceptional support and the trust underlying our work. I wish him all the best with his new plans and all professional and personal endeavors.”
Dr. Frank Mathias, CEO of Rentschler Biopharma, added: “I am personally delighted to welcome Alexander to Rentschler Biopharma as he is a great addition to our team. We are impressed by his broad experience in building healthcare businesses and effectively managing change, which will be a significant asset to our company as we grow and add new services to meet the evolving needs of our clients and their patients. Alexander fully endorses our ‘Strategy 2025’ and we look forward to further bringing it to life together!”
Alexander Dettmer, newly appointed CFO of Rentschler Biopharma, commented: “I am excited to join Rentschler Biopharma, a company with a great reputation and track record, that I have been familiar with for many years. We share the long-term commitment to innovation and growth as well as the future vision. Shaping a leading global company, with a sustainable competitive position in today’s highly dynamic CDMO market, is very compelling. I find that Rentschler Biopharma combines the potential of a fast-growing, international, entrepreneurial company with the stability of a successful, well-managed, family-owned operation. I look forward to working with this committed team to execute on the company’s strategy, drive growth and exceed client expectations.”
Prior to joining Rentschler Biopharma, Mr. Dettmer successfully held several senior leadership positions within the Fresenius SE & Co. KGaA group, which he joined in 2005. His last role was Senior Vice President Corporate Business Development/M&A, where he led the broader M&A team that managed M&A transaction processes. Previous to that, he was CFO of Fresenius Kabi’s Medical Devices Division, Executive VP Finance, Procurement & HR, where his responsibilities included financial planning, controlling, compliance, strategic purchasing and product partnering. Before that, he was CFO and Managing Director at Fresenius Biotech GmbH (now: Neovii Biotech). Mr. Dettmer studied in Boston, MA, USA as well as in Singapore and holds a Diploma in Economics and Business Administration (Lic. Oec.) from the University of St. Gallen (HSG), Switzerland.
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees. For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.
Contact:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
Phone: +49-7392-701-874
communications@rentschler-
Media inquiries:
MC Services AG
Eva Bauer
Phone: +49-89-210228-0
rentschler@mc-services.eu
U.S.
Laurie Doyle
Phone: +1-339-832-0752
If you wish to be removed from the Rentschler distribution list, please click here.
In accordance with the new EU General Data Protection Regulation (GDPR), we ask for your consent to continue sending you press releases and other information. If we do not receive any feedback from you, we will continue to send you press releases in the future. You can revoke your consent to receive information and to store data at any time and without giving reasons by e-mail to contact@mc-services.eu.
